- Home
- SHLS vs VRDN Comparison
SHLS vs VRDN Comparison
Compare SHLS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHLS | VRDN |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SHLS | VRDN |
|---|---|---|
| Price | $7.91 | $18.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $9.07 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 4.7M | 2.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $475,331,000.00 | $5,706,000.00 |
| Revenue This Year | $26.24 | $13.73 |
| Revenue Next Year | $11.52 | $279.00 |
| P/E Ratio | $41.63 | ★ N/A |
| Revenue Growth | ★ 19.07 | N/A |
| 52 Week Low | $3.81 | $11.76 |
| 52 Week High | $11.36 | $34.29 |
Technical Indicators
Market Signals| Indicator | SHLS | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 63.78 | 57.73 |
| Support Level | $7.24 | $17.91 |
| Resistance Level | $9.80 | $19.42 |
| Average True Range (ATR) | 0.51 | 0.70 |
| MACD | 0.11 | 0.75 |
| Stochastic Oscillator | 59.25 | 75.66 |
Price Performance
Historical ComparisonAbout SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.